AU603956B2 - Creación de Inventos y Patentes con Inteligencia Artificial

AU603956B2 – Avermectin and milbemycin derivatives from streptomyces avermitiosis ATCC 31267, 31271 and 31272
– Google Patents

AU603956B2 – Avermectin and milbemycin derivatives from streptomyces avermitiosis ATCC 31267, 31271 and 31272
– Google Patents
Avermectin and milbemycin derivatives from streptomyces avermitiosis ATCC 31267, 31271 and 31272

Download PDF
Info

Publication number
AU603956B2

AU603956B2
AU37840/89A
AU3784089A
AU603956B2
AU 603956 B2
AU603956 B2
AU 603956B2
AU 37840/89 A
AU37840/89 A
AU 37840/89A
AU 3784089 A
AU3784089 A
AU 3784089A
AU 603956 B2
AU603956 B2
AU 603956B2
Authority
AU
Australia
Prior art keywords
formula
compound
absent
group
alpha
Prior art date
1988-07-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Application number
AU37840/89A
Other versions

AU3784089A
(en

Inventor
Christopher James Dutton
Stephen Paul Gibson
Nigel Derek Arthur Walshe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pfizer Inc

Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1988-07-05
Filing date
1989-07-04
Publication date
1990-11-29

1989-07-04
Application filed by Pfizer Inc
filed
Critical
Pfizer Inc

1990-05-03
Publication of AU3784089A
publication
Critical
patent/AU3784089A/en

1990-11-29
Application granted
granted
Critical

1990-11-29
Publication of AU603956B2
publication
Critical
patent/AU603956B2/en

2009-07-04
Anticipated expiration
legal-status
Critical

Status
Ceased
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS

C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof

C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen

A—HUMAN NECESSITIES

A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING

A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS

A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds

A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system

A—HUMAN NECESSITIES

A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES

A23K—FODDER

A23K20/00—Accessory food factors for animal feeding-stuffs

A23K20/10—Organic substances

A23K20/195—Antibiotics

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P33/00—Antiparasitic agents

Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC

Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

Y10S435/00—Chemistry: molecular biology and microbiology

Y10S435/8215—Microorganisms

Y10S435/822—Microorganisms using bacteria or actinomycetales

Y10S435/886—Streptomyces

Description

(Acr r» S F Ref: 98102 FORM COMMONWEALTH OF AUSTRALIA PATENTS ACT 1952 COMPLETE SPECIFICATION
(ORIGINAL)
FOR OFFICE USE: Class Int Class S Complete Specification Lodged: Accepted: Published: 46 SPriority: «4, j.ii B ‘i Related Art: Name and Address of Applicant: *0 0 0 Pfizer Inc.
235 East 42nd Street New York New York 10017 UNITED STATES OF AMERICA Spruson Ferguson, Patent Attorneys Level 33 St Martins Tower, 31 Market Street Sydney, New South Wales, 2000, Australia o* Address for Service: 2.4. Complete Specification for the invention entitled: «Avermectin and Milbemycin Derivatives from Streptomyces cvermitiosis ATCC 31267, 31271 and 31272.
The following statement is a full description of this invention, including the best method of performing it known to me/us 5845/5
I
Abstract Antiparasitic compounds of formula
CH
3
OH
3 ea..
00 .0 0.0 0 R,
(I)
The broken line at the 22-23 position representing an optional double bond and either R 1is H or OH and the double bond is absent or the double bond is present and R 1is absent; R 2is optionally substituted phenyl, or a group of formula (II): Does 0 00 00 0 (Cl’,(cH 2 c (CHab (CH~d (11I) 0 0 -0 4~ 0*41 wherein X is 0, S or -CHR 2 abc and d are 0-2 and R 3is H or Me R 4is H, OH or 4 1-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy.
The compounds are prepared by fermentation of Streotomyces avermitilis in the presence of an N-alkanoyl cysteamine thioester containing R2.
PLC 479
I
i ‘Avermectin and Milbemycin Derivatives from Streptomyces avernitiosis ATCC 31267, 31271 and 31272.
DESCRIPTION
This invention relates to antiparasitic agents and in particular to compounds related to the avermectins and milbemycins, but having a novel substituent group at the and to a process for their preparation.
The avermectins are a group of broad spectrum antiparasitic agents referred to previously as the C-076 compounds. They are produced by fermenting a strain of the microorganism Streptomyces avermitilis ATCC 31267, 31271 or 31272 under aerobic conditions in an aqueous nutrient medium containing inorganic salts and 0°o assimilable sources of carbon and nitrogen. The morphological and o 00 cultural properties of the strains ATCC 31267, 31271 and 31272 are 00 00 o described in detail in British Patent Specification no. 1573955 which also describef the isolation and the chemical structure of the-eight individual components which make up the C-076 complex.
The milbemycins are structurally related macrolide S t antibiotics lacking the sugar residues at the 13-position. They may be produced by fermentation, for example, as described in British Patent Specification 1390336 and European Patent Application 170006.
The aglycones are derivable from the avermectins by hydrolysis to remove the sugar residues to produce a similar compound having a hydroxy group at the 13-position.
In our European Patent Application publication no. 0214731 we disclose that by adding certain specified carboxylic acids, or derivatives thereof, to the fermentation of an avermectin producing organism it is possible to obtain novel compounds, PLC 479 11 2 related to the avermectins but having an unnatural substituent group at the 25-position in place of the isopropyl or sec-butyl group which is normally present.
The novel compounds produced are characterised in that the substituent group at the 25-position is alpha-branched i.e. the carbon atom attached to the C-25 ring position is a secondary carbon atom linked to two further carbon atoms.
PubishkeX In our co-pending European patent application nos.
Z .7G(o3 o, k21613 .3C I and 300 426. we describe and claim new mutant strains of the microorganism Streptomyces avermitilis lacking qO.e branched-chain 2-oxo acid dehydrogenase activity. Said strains have been deposited in the American Type Culture Collection, r’ Rockville, Maryland under the designations Streptomyces avermit.lis ATCC 53567, ATCC 53568 and ATCC 53692. In our British patent application 87.26730 we disclose that, by using chese new mutant strains of Streptomyces avermitilis it is possible to obtain a further range of novel avermectin derivatives, not previously obtainable, wherein the C-25 substituent is linked by an unbranched (primary) carbon atom. These avermectins are prepared by fermenting the afore-mentioned microorganisms in the presence of the appropriate carboxylic acid or a salt, ester or amide thereof or oxidative precursor therefor. It has now been I discovered that certain carboxylic acids, which do not incorporate Swhen added to the fermentation as the free carboxylic acid or a simple ester or thioester, will produce novel avermectins if added in the form of an N-alkanoyl cysteamine thioester.
7C/ 0 PLC 479 N-alkanoyl cysteamine thioesters have been used in biosynthetic studies for other purposes, see R. C. Hutchinson et.
al., J. Amer. Chem. Soc., 1987, 109, 1253-1255 or D. E. Cane et.
al. J. Amer. Chem. Soc., 1987, 109, 1255-1257 or J. A. Robinson et. al., J. Chem. Soc., Chem. Comm. 1988, 4.
The novel compounds so produced are active antiparasitic agents having particular utility as anthelmintics, ectoparasiticides, insecticides, acaricides and animal growth promoting agents. The compounds can be subjected to conventional chemical transformation reactions to obtain further novel semi-synthetic derivatives. Thus, according to one aspect of the present invention there are provided compounds having the formula 0
O
SOOH
(I)
wherein the broken line at the 22-23 position represents an optional double bond and wherein either R1 is H or OH and the double bond is absent, or, the double bond is present and R 1 is absent;
R
2 is phenyl which may optionally be substituted with at least one substituent selected from PLC 479 MW- C -C alkyl, C -C 4 alkoxy and C 1
-C
4 alkylthio groups, halogen atoms, trifluoromethyl, and cyano; 2 may be a group of formul (II): R may be a group of formula (II): (CH a (CH2)c (CH2) b (CH2d
(II)
4 4 t t #1 wherein X is 0, S or -CH 2 and a, b, c and d may each independently be 0, 1 or 2; the sum of a, b, c and d not exceeding 3 R is hydrogen or methyl; 4 R is H, OH or a 4′-(alpha-L-oleandrosyl)-alpha-Loleandrosyloxy group of the formula: f CH 0 3 In the above definition, alkyl groups containing 3 or more carbon atoms may be straight nr branched chain. Halo means fluoro, chloro, bromo or iodo, PLC 479 The C-076 complex comprises eight distinct but closely related compounds described as C-076 Ala, Alb, A2a, A2b, Bla, Bib, B2a and B2b. The series of compounds refers to the natural avermectin wherein the 25-substituent is (S)-sec-butyl and the «b» series to those wherein the 25-substituent is isopropyl. The designations and refer to avermectins wherein the is methoxy or hydroxy, respectively, and the numeral refers to avermectins wherein a double bond is present at the 22-23 position, and numeral to avermectins having a hydrogen at the 22-position and hydroxy at the 23 position.
In this application, the and identifiers have been cp dropped. Identifiers Al, A2, Bl and B2 have been retained to S°refer to non-natural avermectins having the structural features 4 corresponding to those of the C-076 avermectins as noted above.
The invention includes compounds of the formula wherein 2 R is phenyl.
‘4 In another group of compounds, R is a group of formula (II) 4 4 wherein a and b are 0; c and d are 1; and X is CH 2 2 In a further group of compounds, R is a group of formula (II) wherein a and b are 0; c is 1; d is 2; and X is CH 2 2’« PLC 479 ;;:~l;iilii.li.iiii -l;;-ill-l .i _I I.I I I. -tL.I.IIIX__IXI (-lil-il 1 In yet another group of compounds, R 2 is a group of formula (II) wherein a and b are 0; c and d are 1; and X is 0.
According to another aspect of the invention the compounds of formula wherein R 1 is OH and the double bond is absent or 1 4 wherein the double bond is present and R is absent and R is 4′-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy are prepared by fermenting a Streptomyces avermitilis mutant organism ATCC 53567, 53568 or 53692, as described in European patent applications 2.-7(o 103 D2 b3\ o 88309354-4 and g88344426-9- in the presence of the appropriate N-alkanoyl cysteamine thioester of the formula (III).
o ft 9 9 6 t R-COS(CH 2 )NHCOR (III) 2 6 wherein R is as defined above, and R is a C1-C1 alkyl group.
The thioester is added to the fermentation either at the time of inoculation or at intervals during the fermentation. Production of the compounds of formula may be monitored by removing samples from the fermentation, extracting with an organic solvent and following the appearance of the compound of formula PLC 479 *900 O 0 Q0 0 *011 to 0 o a 0 5 by chromatography, for example using high pressure liquid chromatography. Incubation is continued until the yield of the compound of formula has been maximised, generally for a period of from 12 to 16 days.
A preferred level of each addition of the thioester is between 0.05 and 4.0 grams per litre. The best yields of the compounds of formula are obtained by gradually adding the acid to the fermentation, for example by daily additions of the thioester over a period of several days. The medium used for the fermentation may be a conventional complex medium containing assimilable sources of carbon, nitrogen and other trace elements.
After fermentation for a period of several days at a temperature preferably in the range of from 24 to 33°C, the fermentation broth is centrifuged or filtered and the mycelial cake is extracted with acetone or methanol. The solvent extract is concentrated and the desired product is then extracted into a water-immiscible organic solvent, such as methylene chloride, ethyl acetate, chloroform, butanol or methyl isobutyl ketone. The solvent extract is concentrated and the crude product containing the compounds of formula is further purified as necessary by chromatography, for example using preparative reverse phase, high pressure liquid chromatography.
The product is generally obtained as a mixture of the compounds of formula wherein R is 4′-(alpha-L-oleandrosyl)alpha-L-oleandrosyloxy, R is OH and the double bond absent or R is absent and the double bond is present and wherein R is H or
CH
3 however the proportions can vary depending on the particular thioester employed and the conditions used in the fermentation.
PLC 479
J
8 When the micro-organism used is ATCC 57692 only the B-type avermectin in which R 3 is H is obtained.
It has been found that a range of thioesters as described by formula (III) may be added to the fermentation to yield avermectins having a range of substituent groups at the position. Examples of particular thioesters which may be employed include the following: 2 6 A thioester of formula (III), in which R is phenyl and R is methyl; A thioester of formula (III) in which R 2 is a group as 4 defined in formula (II) in which a and b are 0, c and d are 1 and 6 X is CH2, and R is methyl; 2 t oa 2 0 a A thioester of formula (III) in which R is a group as a oot defined in formula (II) in which a and b are 0, c is 1, d is 2 and X is CH 2 and R 6 is methyl; and a thioester of formula (III) in which R 2 is a group as e defined in formula (II) in which a and b are 0, c and d are 1 and X is 0 and R 6 is methyl.
In one particular and preferred aspect of the invention, the fermentation is performed in the presence of a thioester of formula (III) in which R is phenyl and R is methyl, to yield predominantly the compound of formula wherein R 1 is OH and the 2 3 4 double bond is absent, R 2 is phenyl, R is H and R is 4′-(alpha-L-oleandrosyl)-alpha-4-oleandrosyloxy, referred to herein as 25-phenyl avermectin B2.
PLC 479 PLC 479 9 In another preferred aspect of the invention, the fermentation is performed in the presence of a thioester of formula (III) in which R 2 is 2-bicyclo[3.1.0]hexyl and R 6 is methyl, to yield predominantly the compound of formula wherein 1 9 R is OH and the double bond is absent, R~ is 2-bicyclo[3.1.0]- 3 4 hexyl, R is H and R is 4′-(alpha-L-oleandrosyl)-alpha-4oleandrosyloxy, referred to herein as 25-(2-bicyclo[3.1.0]hexyl)avermectin B2.
Thioesters of formula (IT) may be prepared from the corresponding carboxylic acids of the formula R -CO 2 H by coupling 0 0 with a thiol of the formula R CONHCH2CH2SH in the presence of a 0000 2 2 0 .0 0 dehydrating agent such as dicyclohexylcarbodiimide in an inert 0 0 0 0 00 solvent or using diphenylphosphorylazide and a base such as oo 00o0 triethylamine in dimethylformamide. Thiols of the formula 06 R CONHCH 2
CH
2 SH may be prepared from cysteamine hydrochloride by treatment with a base such as triethylamine followed by o0 trimethylsilyl chloride then an acid chloride of the formula o 6 6 0 R COC1 and a further amount of a base such as triethylamine. The resulting crude thioester is then purified by, for example, column chromatography on silica gel.
Carboxylic acids of the formula R CO2H in which R 2 is a group of formula wherein a and b are 0, and c, d and X are as previously defined may be prepared by the addition of alkyl diazoacetate esters to cycloalkenes of the formula CH=CH(CH X(CH2 d in the presence of rhodium (II) acetate, followed by cleavage of the resultant alkyl esters, PLC 479 The resultant carboxylic acid may then be purified by conventional means, for example distillation or crystallization.
Preparation of bicyclo[3.1.0]hexane-2-carboxylic acid is described in J. Amer. Chem. Soc., 85, 582-585, 1963 (Meinwald J., Labana Chadha M.S).
Compounds of the formula wherein the double bond is present and R 1 is absent may alternatively be prepared from the corresponding compound of formula wherein R 1 is OH and the double bond is absent by a dehydration reaction. The reaction is performed by first selectively protecting the hydroxyl groups at a 4 the 5 and 4″ positions, e.g. as the t-butyldimethylsilyloxy acetyl .ne derivative, then reacting with a substituted thiocarbonyl halide, such as (4-methylphenoxy)thiocarbonyl chloride, followed by oo. heating in a high boiling point solvent, e.g. trichlorobenzene, to effect the dehydration. The product is finally deprotected to give the unsaturated compound. These steps together with Sapproprial reagents and reaction conditions are described in I United States patent 4328335.
4C 33 The compounds of formula I wherein R is H may also be prepared from the corresponding compounds wherein R is CH 3 by demechylation. This reaction is achieved by treating the 5-methoxy compound, or a suitably protected derivative thereof, with mercuric acetate and hydrolysing the resulting 3-acetoxy enol ether with dilute acid to give the 5-keto compound. This is then reduced using, for example, sodium borohydride to yield the derivative. Appropriate reagents and reaction conditions for these steps are described in United States patent 4423209.
PLC 479 r.
11 The compounds of formula I wherein R is H and the double bond is absent can be prepared from the corresponding compound wherein the double bond is present and R 1 is absent, by selective catalytic hydrogenation using an appropriate catalyst. For example the reduction may be achieved using tris(triphenylphosphine)rhodium chloride as described in European patent application publication no. 0001689.
The compounds of formula wherien R is H may be prepared from the corresponding compounds wherein R 4 is 4′-(alpha-Loleandrosyl)-alpha-L-oleandrosyloxy by removing the I 4’-(alpha-L-oleandrosyl)-alpha-L-oleandrose group by mild hydrolysis with an acid in an aqueous organic solvent to yield the aglycone wherein R is OH; this is then halogenated, for example by reacting ‘Jith a benzene sulphonyl halide, to yield the 13-deoxy-13-halo derivative which is finally selectively reduced, for example using tributyltin hydride. In order to avoid unwanted side reactions it is desirable to protect any other hydroxy groups s S’ which may be present, for example using a tert-butyldimethylsilyl group. This is then readily removed after the halogenation or reduction step by treatment with methanol containing a trace of acid. All these steps together with appropriate reagents and reaction conditions for their performance are described in S..European patent application publication no. 0002615.
The compounds of the invention are highly active antiparasitic agents having particular utility as anthelmintics, ectoparasiticides, insecticides, acaricides, and animal growth promoters.
PLC 479 l~rrrrri lr~ri;-~-XP~ lrrP+II^-Lli ii.l .C ITi. .IPrm~-l *12 Thus the compounds are effective in treating a variety of conditions caused by endoparasites including, in particular, helminthiasis which is most frequently caused by a group of parasitic worms described as nematodes and which can cause severe economic losses in swine, sheep, horses and cattle as well as affecting domestic animals and poultry. The compounds are also effective against other nematodes which affect various species of animals including, for example, Dirofilaria in dogs and various r parasites which can infect humans including gastro-intestinal parasites such as Ancylostoma, Necator, Ascaris, Strongyloides, o Trichinella, Capillaria, Trichuris, Enterobius and parasites which are found in the blood or other tissues and organs such as o 0 filiarial worms and the extra intestinal stages of Strongyloides 0 D 0o and Trichinella.
0 The compounds are also of value in treating ectoparasite infections including in particular arthropod ectoparasites of animals and birds such as ticks, mites, lice, fleas, blowfly, Co biting insects and migrating dipterous larvae which can affect cattle and horses.
The compounds are also insecticides active against household pests such as the cockroach, clothes moth, carpet beetle and the housefly as well as being useful against insect pests of stored grain and of agricultural plants such as spider mites, aphids, caterpillars, fire ants, termites and against migratory orthopterans such as locusts.
The ccmpounds of formula are administered as a formulation appropriate to the specific use envisaged and to the particular species of host animal being treated and the parasite PLC 479 00tg 0 a 0 0 D a3 0 00 0 i o 00 0 0 06 or insect involved. For use as an anthelmintic the compounds may be administered orally in the form of a capsule, bolus, tablet or preferably a liquid drench, or alternatively, they may be administered by injection or as an implant or as a pour-on formulation. Such formulations are prepared in a conventional manner in accordance with standard veterinary practice. Thus capsules, boluses or tablets may be prepared by mixing the active ingredient with a suitable finely divided diluent or carrier, additionally containing a disintegrating agent -nd/or binder such as starch, lactose, talc, magnesium stearate etc. A drench formulation may be prepared by dispersing the active ingredient in an aqueous solution together with dispersing or wetting agents etc. and injectable formulations may be prepared in the form of a sterile solution which may contain other substances, for example, enough salts or glucose to make tre solution isotonic with blood.
These formulations will vary with regard to the weight of active compound depending on the species of host animal to be treated, the severity and type of infection and the body weight of the host. Generally for oral administration a dose of from about 0.001 to 10 mg per Kg of animal body weight given as a single dose or in divided doses for a period of from 1 to 5 days will be satisfactory but of course there can be instances where higher or lower dosage ranges are indicated and such are within the scope of this invention.
As an alternative the compounds may be administered with the animal feedstuff and for this purpose a concentrated feed additive or premix may be prepared for mixing with the normal animal feed.
01 O a PLC 479
I
14 For use as an insecticide and for treating agricultural pests the compounds are applied as sprays, dusts, emulsions and the like in accordance with standard agricultural practice.
For use as a growth promotant or for improving the lean meat to fat ratio in farm or domestic animals, the compounds may be administered with the animal feedstuff or drinking water.
Alternatively, they may be administered orally in the form of a capsule, bolus, tablet or liquid drench, or parenterally by injection or as an implant.
For human use the compounds are administered as a pharmaceutically acceptable formulation in accordance with normal aoo, medical practice.
oo, The invention is illustrated by the following Examples in oooo which Example 1 is an Example of the preparation of a compound of st the formula Example 2 is an example of the preparation of Sanother compound of formula Example 3 is an example of a ij drench formulation and Examples 4 and 5 illustrate the ji antiparasitic and insecticidal activity of the compounds of i Examples 1 and 2.
i
I~
PLC 479 r, _ifl EXAMPLE 1 f- 0 00 0oeo 00oo00 o oo 0 0 0 o 0 oo 0 00 00 oo t t fsr avermectin B2 A frozen inoculum (2 ml) of a culture of Streptomyces avermitilis mutant organism ATCC 53568 was inoculated into 50 mis of a medium containing starch (1 Pharmamedia (Trademark) (0.75 ardamine pH (0.25 and calcium carbonate (0.1 g) in a 300 ml flask and incubated at 28°C for 2 days. This inoculum ml) was transferred to a second inoculum flask (1 litre) containing s:arch (20 Pharmamedia (15 ardamine pH (5 g) and calcium carbonate (2 g) and incubated at 280C for a further 2 days. This inoculum was used to inoculate 70 litres of a medium containing starch (7 kg), magnesium sulphate (70 Pharmamedia (350 dipotassium hydrogen phosphate (70 ferrous sulphate (0.7 calcium carbonate (490 glutamic acid (42 zinc sulphate (0.07 g) and manganous sulphate (0.07 g) contained in a 70 litre fermenter. The fermentation was incubated at 28 0 C, with agitation at 350 r.p.m. and aeration at 70 litres per minute.
S-Benzoyl N-acetyl cysteamine (24 g) was added after 24 hours.
After 288 hours the mycelium was removed by filtration and extracted with acetone (2 x 50 litres). The acetone extract was concentrated to approximately 10 litres and extracted with ethyl acetate (30 litres) in three portions. The resulting ethyl acetate layers were combined and evaporated to give a brown oil (97.5 g).
PLC 479 16 The latter was dissolved in methylene chloride (1200 ml) and stirred with silica gel (100 g) and charcoal (100 g) for 1 hour.
The silica and charcoal were removed by filtration through Arbacel and the filtrate was evaporated to give a yellow oil (74.5 g).
The latter was dissolved in 100 ml petrol 40-60*C) and filtered. The filtrate was added to a 500 g alumina (Woelm. Akt.
B) column and eluted with petrol 60-80 0 (1.5 litre), ethyl acetate (2 litres) and finally methanol (1 litre). Relevant fractions were combined to give 4.12 g of a pale brown oil. This was dissolved in methanol (200 ml) and cooled to -75°C. A waxy precipitate appeared and was filtered off. The filtrate was 0000 evaporated to give 2.98 g of a mobile oil which was dissolved in 0000 0000 diethyl ether and added to a column of silica gel (35 g) and 0 0 0 4 0 0f °0 eluted with diethyl ether. Fractions (100 ml) were collected and 0 O 0°o fraction numbers 13 to 20 were combined and evapora ,ted to yield 0 0 401 0 partially purified material. The product was dissolved in methanol (0.7 mm) and chromatographed on a C18 Zorbax ODS (Trademark, Dupont) column (21 mm x 25 cm) eluting with a mixture of methanol and water (75:25) at a flowrate of 9 ml per minute.
ml Fractions were collected and fractions 86 to 96 were combined and evaporated to yield a compound of formula wherein 1 2 34 R is OH, the .uble bond is absent, R is phenyl, R 3 is H and R’ is 4′-(alpha-L-oleandrosy!)-L-oleandrosyloxy, as a white powder, m.p. 150-155 0 C. The structure of the product was confirmed by fast atom bombardment mass spectrometry, performed on a VG Model 7070E mass spectrometer using a sample matrix of triethylene gl,-co! with solid sodium chloride. (M Na) observed at m/e 933 (theoretical 933).
PLC 479 t> 1 17 Electron impact mass spectrometry was performed using a VG Model 7070F mass spectrometer. The m/e values for the principal fragments were: 343, 325, 259, 241, 231, 145, 127, 113, 111, and 87.
EXAMPLE 2 2 5-( 2 -Bicyclo[3.1.0]hexyl)avermectin B2 A frozen inoculum (2 ml) of a culture of Streptomyces avermitilis mutant organism ATCC 53568 was inoculated into 50 mis of a medium containing starch (1 Pharmamedia (Trademark) (0.75 ardamine pH (0.25 and calcium carbonate (0.1 g) in a ooo0 300 ml flask and incubated at 28°C for 2 days. This inoculum 0000 ml) was transferred to a second inoculum flask (1 litre) 0000 0,0o° containing starch (20 Pharmamedia (15 ardamine pH (5 g) 0o a and calcium carbonate (2 g) and incubated at 28 0 C for a further 2 o o days. This inoculum was used to inoculate 100 litres of a medium containing starch (10 kg) magnesium sulphate (100 Pharmamedia (500 dipotassium hydrogen phsophate (100 ferrous sulphate C rr calcium carbonate (700 g) glutamic acid (60 zinc sulphate (0.1 g) and manganous sulphate (0.1 g) contained in a 100 litre fermenter. The fermentation was incubated at 28 0 C with agitation at 200 r.p.m. and aeration at 80 litres per minute. The SN-acetyl cysteamine thioester of bicyclo[3.1.0]hexane carboxylic acid (16 g) was added after 43 hours, and again at 115 hours (16 After 234 hours the mycelium was removed by filtration and extracted with acetone (2 x 50 litres). The acetone extract was concentrated to approximately 10 litres and extracted with ethyl acetate (3 x 15 litres). The resulting ethyl acetate layers PLC 479 0. y 18 were combined and evaporated to give a brown oil (67.8 The oil was dissolved in petroleum ether 40-60 0 C) (250 ml) and chromatographed on alumina (340 Unwanted material was eluted with a mixture of ethyl acetate and dichloromethane and the product eluted with a mixture of ethyl acetate and methanol After evaporation a pale brown oil (17.8 g) was obtained which was re-dissolved in petroleum ether 40-60 0 C) and chromatographed on silica gel (460 Unwanted materials were eluted with petroleum ether 40-60°C), followed by diethyl ether. The product was eluted with a mixture of ethyl acetate and diethyl ether After evaporation an off-white foam was obtained oeo, (1.3 which was dissolved in methanol (4 ml) and purified by 0000 0co° chromatography using a C-18 Dynamax (Trademark Rainin) column 000 a .0 0 0 00 0o0 (41.4 mm x 25 cm), eluting with a mixture of methanol and water 0o oo (80:20) at a flowrate of 60 ml/min. Relevant fractions were oo o1 0000 0 combined to yield a compound of formula wherein R is OH, the 2 3 4 double bond is absent, R is 2-bicyclo[3.1.0]hexyl, R is H and R 4 is 4′-(alpha-L-oleandrosyl)-L-oleandrosyloxyl as a white powder, m.p. 173-176°C (decomp). The structure of the procuct was confirmed by fast atom bombardment mass spectrometry performed on Sa VG Model 7070E mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M Na) observed at m/e 937 (theoretical 937).
So0 Electronic impact mass spectrometry was performed using a VG Model 7070 F mass spectrometer. The m/e values for the principal fragments were: 608, 480, 347, 329, 263, 257, 179, 145, 127, 113, and 87.
PLC 479 19 EXAMPLE 3 Drench Formulation The product of the preceding Examples 1 and 2 were dissolved in polyethylene glycol (average molecular weight 300) to give solutions containing 400 micrograms/ml for use as drench formulations.
EXAMPLE 4 Anthelmintic Activity Anthelmintic activity was evaluated against Caenorhabditis elegans using the in vitro screening test described by K. G.
oo0 Simpkin and G. L. Coles in Parasitology, 1979, 79, 19. The oooo000 -«So products of Examples 1 and 2 killed 100% of the worms at a well 000 0 0oo 6 concentration of 0.1 micrograms per ml.
S0 0 0 EXAMPLE Insecticidal Activity Activity against the larval stage of the blowfly Lucilia cuprina (Q strain) is demonstrated using a standard procedure in which first instar larvae are kept in contact with filter paper treated with test compound. The test compound is first applied to the paper as an acetone solution. The treated filter papers are then placed into tubes containing 1 ml of newborn calf serum and the first instars are added. The products of Examples 1 and killed 100% of the larvae when applied to the filter paper at a level of 1 milligram per square metre.
r PLC 479 I_
PREPARATIONS
Preparation of S-benzoyl N-acetyl cysteamine Cysteamine hydrochloride (50 g) in dry methylene chloride (800 ml) was treated at 0 to 5 0 C with triethylamine (140 ml) and the slurry stirred for hour. Trimethylsilyl chloride (72 ml) was then added with a further 100 ml of methylene chloride over a period of 20 mintutes at 0°C. Stirring was continued at 0 C for 1 hours. Acetyl chloride (31 ml) is 100 ml methylene chloride was then added at 0-5°C over a period of 20 minutes, then triethylamine (61 ml) was added at the same temperature. The resulting white slurry was stirred vigorously for 2 hours at room 000000 temperature. Water (50 ml) was then added and the mixture 00ooo00 evaporated to dryness in vacuo. The resulting white solid was 000 treated with saturated brine (200 ml) and extracted with ethyl acetate (400 ml). The aqueous layer was then extracted again with Sethyl acetate (3 x 400 ml) and the combined organic layers were dried over anhydrous sodium sulphate, filtered and evaporated to gile N-acetyl cysteamine a pale yellow oil, which was distilled to 1 -give 27 g of clear oil B.pt. 103-108 0 C/0.8 mmHg.
Benzoic acid (51.6 g) and 100 g of N-acetyl cysteamine were dissolved in dimethylformamide (100 ml) and methylene chloride (300 ml). The resulting mixture was stirred under nitrogen at OC and 184 ml of diphenylphosphorylazide was added slowly, followed after 5 minutes by 238 ml of triethylamine. The temperature was maintained below 10 0 C. The mixture was then stirred overnight at room temperature under nitrogen. The mixture was diluted with 100 ml methylene chloride and washed with 400 ml 5% aqueous citric PLC 479 21 acid, saturated sodium bicarbonate solution (400 ml) and saturated sodium chloride solution (400 ml), then dried over anhydrous sodium sulphate and concentrated to a yellow oil. The oil was applied to a 1 kg column of silica gel and eluted with 2% ethyl acetate in methylene chloride increasing to 100% ethyl acetate.
Fractions 6 to 19 were combined to give 128 g of waxy solid. This was mixed with 40 g of arbacel and extracted with hexane using a soxhlet extractor.
The extract was evaporated to give 101.7 g of the title compound as a white solid. M.pt. 54-57 0 C. The structure of the product was confirmed by fast atom bombardment mass spectrometry performed on a VG model 7070E mass spectrometer using a sample 0000 0 0 o0aoo 00.0 matrix of triethylene glycol.
ooo0 Qoa 0000 A strong MH signal was seen at m/e 224 (theoretical 224).
0 0 o 0 00 0 9 9 T Preparation of Bicyclo[3.l.0]hexane carboxylic acid, N-acetyl cysteamine thioester Bicyclo[3.1.0]hexane carboxylic acid (1.1 diphenylphosphorylazide (4.9 g) and N-acetyl cysteamine (2 g) were stirred in dimethylformamide (5 ml) at 0 C. Triethylamine (5 ml) was added dropwise and stirring was continued at ambient temperature for 24 hours. The reaction mixture was diluted with toluene (100 ml) and the solution washed with 5% aqueous citric acid (100 t ml), saturated sodium bicarbonate solution (100 ml) and finally, saturated brine (100 ml). Then the organic layer was separated, dried over sodium sulphate, filtered and evaporated. The residue (2.2 g) was purified by chromatography on silica (50 eluting PLC 479 S22 with methylene chloride and ethyl acetate (a gradient of ethyl acetate from 2 to The fractions were analysed by thin layer chromatography and fractions 13 to 20 were combined to give the product as an oil (1.2 g).
The structure of the product was confirmed by electron impact mass spectrometry using a VG Model 7070 F mass spectrometer. The m/e value for the molecular ion was 227 (theoretical 227) and the principal fragments were: 184, 168, 119, 109 and 81.
o y, jgl o o 00 84 Siii PLC 479 *t 23 It will be appreciated from the foregoing that what we will claim may include the following:- The novel compounds of the formula as herein defined.
Processes as described herein for preparing the novel compounds of the formula Novel ectoparasiticidal, insecticidal, acaricidal or anthelmintic or growth promoter compositions, including oral, injectable and pour-on formulations, concentrates and animal feeds as described herein.
A compound of the formula for use in treating an animal to combat ectoparasite or helminth infestations.
9 t*1 A method of combating animal ectoparasite and helminth r infestations, or of growth promotion, which comprises treating the animal with an effective amount of a compound of the formula A method of combating crop pests which comprises applying an effective amount of a compound of the formula li /i PLC 479

Claims (6)

1. A compound of formula R 4 CH 221, C(H, wherein~ Uh rknln tte2-3psto ersnsa doubleind ise bent or, a the double boion ispresents anRi absent; Ris phenyl which may optionally be substituted with at least one osubstituent selected from C c alkyl, C,-C alkoxyv and C C 1 4 4 1 4+ C ,,alkylthio groups, f~ 1 uoro, chloro, bromo, iodo, trif’luoromethyl and cyano; or R 2is a group or formula (CHip (CH 2 a wherein X is 0, S or -CH and a, b, c and d nay each 2 independently be 0, 1or 2; the sum of a b c and d not exceeding PLC 479 R 3 is hydrogen or methyl; 4 1 and R is H, OH or a 4 .(alpha-L-oleandrosyl)-alpha-L oleandrosyloxy group of the formula: CEC 0 0 C:Z.0 CE: 0 3 7 2. A compound according to cliRi hc is phenyl1.

3. A compound according to claim 1, in which R~ is a group of ormula wherein a and b are 0, c and d are I and X is -CH «2

0004. A compound according to claim 1, in which ?R is a group of 000 ormula (II) wherein a and b are 0, c is 1, d is 2 and X is- -CH 2-

0000005. A compound accordi.ng to claim I, in which T.iR gopo 0 0 0 0 -formula wherein a and b are 0, c and d are 1, and X is 0. 0 2-Phenyl aver-.ectin B2.

7. 25-(2-3i’cyclor3.l-.O]hexyl)aver-mectin,

32. 8. A process for preparingl a comp-ound of f-ormula as claimed in claim 1, which comprises te-n-enting a Streotomyces averm-irili mutant organism ATCC 53567, 53568 or 53692- in the presence of an N-ailkanovl cysteamine thioester or -formula (III): 6 R COS CF 9 mCOR 2. 6 wherein R as deffined as above and R is a C alkyl group, 000 1 10 and isolating the compound of -Formula wherein R 1 is OH and the double bond is absent, or wherein the double bond i s present: and R 1is absent, and R 4 is 4 1-(alpha-L-oleandrosyl)-alpha-L- oleandrosy-loxy, followed if- necessary by one or more of the following steps: PLC 479 h 26 subjecting said COrnpouiud in which the dcubl: bond is absent positions being selectively protected during the dehydration, o yield a compound of formula in w~hich the double bond is present aind R is absent, (io’i) dEMethylating- sai:d comDound in whiLch R 3 c methv’ to produce a compound of fo_-nla in whi-h R- is H, ii)sub~ec:- ng saic comoounc f in the ‘Coute nDon6 -sPresent to selec:ive catav::r nvrgnto oV~cacmon ro rmu 1a i n whi’n h:e double bond is abos en a ndK: ()hyjdro!7sing said comnound wnzcn L-al oha -1-c eand ro sy’) -a !Dha -L -lean dro syloxv to V-e4c comnoundof 0:or-mua i n wn7hcn s H ()halogenaringj a omDound obcZZined from stan -0v 😮 yieda lb Olt 13-deox-K3-haio derivative and SE’eC:-_Ve» reoulciD2 Said derivtv to VieldC a com’Dounc 0: :c0 u ~)In Whc 11i 9. A omositifon for the treatment and pre-vent-ion of narasitic infections in humans and anima-IS, zincludinz ectovarasiticidal, insecticidal, acar-fcidal adanthElzintic comnositi:-_ons,whc comnries a compound of frua ascLai*med: in any one of t 7 together with an inert diluent or carrier. 110,A composition as claimed in ciaim 9 iLn thne form of a liouid d1 rench or an oral or injecrable orzulation, or i*n the :ozr or.- an ani~mal feedstuff or m.remix or sunni~ement for addi~tion to anima:I to 7 for use in the tre prevencion oz oarasl:ic 74p,.C ?LC /479 27 11. A method of combating insect or parasitic infections or infestations, including parasitic conditions in humans and animals and agricultural or horticultural pest infestations, which comprises applying an effective amount of a compound of formula as claimed in any one of claims 1 to 7 or of a composition as claimed in claim 9 or claim 10 to the organism responsible for said infection or infestation or to the location thereof. 12. 25-Substituted avermectin derivatives substantially as hereinbefore described with reference to any one of the Examples. 13. A process for preparing 25-substituted avermectin derivatives substantially as hereinbefore described with reference to any one of the Examples. 14. A 25-substituted avermectin derivative when produced by the process of claim 8. DATED this THENTY-SEVENTH day of AUGUST 1990 Pfizer, Inc. t 9, Patent Attorneys for the Applicant SPRUSON FERGUSON tm J—2 TMS/1387R

AU37840/89A
1988-07-05
1989-07-04
Avermectin and milbemycin derivatives from streptomyces avermitiosis ATCC 31267, 31271 and 31272

Ceased

AU603956B2
(en)

Applications Claiming Priority (2)

Application Number
Priority Date
Filing Date
Title

GB8815967

1988-07-05

GB888815967A

GB8815967D0
(en)

1988-07-05
1988-07-05
Antiparasitic agents

Publications (2)

Publication Number
Publication Date

AU3784089A

AU3784089A
(en)

1990-05-03

AU603956B2
true

AU603956B2
(en)

1990-11-29

Family
ID=10639888
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU37840/89A
Ceased

AU603956B2
(en)

1988-07-05
1989-07-04
Avermectin and milbemycin derivatives from streptomyces avermitiosis ATCC 31267, 31271 and 31272

Country Status (14)

Country
Link

US
(3)

US4980370A
(en)

EP
(1)

EP0350187B1
(en)

JP
(1)

JPH0694466B2
(en)

AR
(1)

AR245131A1
(en)

AT
(1)

ATE99694T1
(en)

AU
(1)

AU603956B2
(en)

CA
(1)

CA1339309C
(en)

DE
(1)

DE68912007T2
(en)

DK
(1)

DK168159B1
(en)

ES
(1)

ES2061997T3
(en)

GB
(1)

GB8815967D0
(en)

IE
(1)

IE63621B1
(en)

NZ
(1)

NZ229807A
(en)

PT
(1)

PT91048B
(en)

Cited By (1)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

AU625983B2
(en)

1989-06-02
1992-07-23
Merck & Co., Inc.
Avermectin derivatives

Families Citing this family (10)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

ES8800986A1
(en)

1985-07-27
1987-12-01
Pfizer
Antiparasitic avermectin and milbemycin derivatives and process for their preparation.

US5840704A
(en)

1986-07-16
1998-11-24
Pfizer Inc.
Antiparasitic agents and process for their preparation

US5830875A
(en)

1989-10-30
1998-11-03
Merck & Co., Inc.
24-and 25-substituted avermectin and milbemycin derivatives

GB9205007D0
(en)

1992-03-07
1992-04-22
Pfizer Ltd
Antiparasitic agents

GB9316129D0
(en)

1993-08-04
1993-09-22
Pfizer Ltd
Antiprasatic agents

RU2120943C1
(en)

1993-10-05
1998-10-27
Пфайзер Инк.
Doramectine derivatives, methods of their synthesis, methods of treatment

DE4427766A1
(en)

1994-08-05
1996-02-08
Basf Ag

Process for the preparation of liquid crystalline mixtures

AP1060A
(en)

1998-01-02
2002-04-23
Pfizer Prod Inc
Novel erythromycin derivatives.

GB9825402D0
(en)

1998-11-19
1999-01-13
Pfizer Ltd
Antiparasitic formulations

US8636081B2
(en)

2011-12-15
2014-01-28
Milwaukee Electric Tool Corporation
Rotary hammer

Family Cites Families (12)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

JPS4914624A
(en)

1972-06-08
1974-02-08

SE434277B
(en)

1976-04-19
1984-07-16
Merck & Co Inc

SET TO MAKE NEW ANTIHELMINTICALLY EFFECTIVE ASSOCIATIONS BY CULTIVATING STREPTOMYCS AVERMITILIS

PH15982A
(en)

1977-10-03
1983-05-18
Merck & Co Inc
Selective hydrogenation producta of c-076 compounds and derivatives thereof

IL56149A
(en)

1977-12-19
1989-09-28
Merck & Co Inc
13-halo and 13-deoxy derivatives of c-076 compounds,their preparation and method for the treatment of parasitic infections in animals therewith

US4328335A
(en)

1979-08-13
1982-05-04
Merck & Co., Inc.
Process for the interconversion of C-076 compounds

US4423209A
(en)

1982-02-26
1983-12-27
Merck & Co., Inc.
Processes for the interconversion of avermectin compounds

DK165119C
(en)

1984-06-05
1993-03-01
American Cyanamid Co

ANTIBIOTIC COMPOUNDS DESIGNED LL-F28249ALFA, BETA, GAMMA, DELTA, EPSILON, ZETA, ETA, THETA, IOTA, KAPPA, MY AND NEW AND PHARMACEUTICAL OR PHARMACOLOGICALLY ACCEPTABLE SALTS THEREOF,

ES8800986A1
(en)

1985-07-27
1987-12-01
Pfizer
Antiparasitic avermectin and milbemycin derivatives and process for their preparation.

GB8606120D0
(en)

1986-03-12
1986-04-16
Glaxo Group Ltd
Process

IN167980B
(en)

1987-01-23
1991-01-19
Pfizer

GB8726730D0
(en)

1987-11-14
1987-12-16
Pfizer Ltd
Antiparasitic agents

EP0353959A2
(en)

1988-08-02
1990-02-07
Beecham Group Plc
Antihelmintic macrolide antibiotics

1988

1988-07-05
GB
GB888815967A
patent/GB8815967D0/en
active
Pending

1989

1989-06-26
ES
ES89306410T
patent/ES2061997T3/en
not_active
Expired – Lifetime

1989-06-26
EP
EP89306410A
patent/EP0350187B1/en
not_active
Expired – Lifetime

1989-06-26
US
US07/371,461
patent/US4980370A/en
not_active
Expired – Fee Related

1989-06-26
AT
AT89306410T
patent/ATE99694T1/en
not_active
IP Right Cessation

1989-06-26
DE
DE89306410T
patent/DE68912007T2/en
not_active
Expired – Fee Related

1989-06-30
CA
CA000604521A
patent/CA1339309C/en
not_active
Expired – Fee Related

1989-07-03
PT
PT91048A
patent/PT91048B/en
not_active
IP Right Cessation

1989-07-04
IE
IE215889A
patent/IE63621B1/en
not_active
IP Right Cessation

1989-07-04
DK
DK330189A
patent/DK168159B1/en
not_active
IP Right Cessation

1989-07-04
AU
AU37840/89A
patent/AU603956B2/en
not_active
Ceased

1989-07-04
NZ
NZ229807A
patent/NZ229807A/en
unknown

1989-07-05
AR
AR89314327A
patent/AR245131A1/en
active

1989-07-05
JP
JP1173860A
patent/JPH0694466B2/en
not_active
Expired – Lifetime

1990

1990-08-29
US
US07/575,039
patent/US5057498A/en
not_active
Expired – Fee Related

1991

1991-06-21
US
US07/718,527
patent/US5112746A/en
not_active
Expired – Fee Related

Cited By (1)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

AU625983B2
(en)

1989-06-02
1992-07-23
Merck & Co., Inc.
Avermectin derivatives

Also Published As

Publication number
Publication date

JPH02288882A
(en)

1990-11-28

US4980370A
(en)

1990-12-25

DK330189A
(en)

1990-01-08

PT91048A
(en)

1990-02-08

ATE99694T1
(en)

1994-01-15

GB8815967D0
(en)

1988-08-10

DK330189D0
(en)

1989-07-04

PT91048B
(en)

1995-01-31

JPH0694466B2
(en)

1994-11-24

CA1339309C
(en)

1997-08-19

EP0350187B1
(en)

1994-01-05

IE63621B1
(en)

1995-05-17

AU3784089A
(en)

1990-05-03

AR245131A1
(en)

1993-12-30

EP0350187A3
(en)

1991-03-27

US5057498A
(en)

1991-10-15

IE892158L
(en)

1990-01-05

DE68912007D1
(en)

1994-02-17

US5112746A
(en)

1992-05-12

DE68912007T2
(en)

1994-04-28

ES2061997T3
(en)

1994-12-16

DK168159B1
(en)

1994-02-21

EP0350187A2
(en)

1990-01-10

NZ229807A
(en)

1990-12-21

Información de contacto